After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious treatment-emergent adverse events (TEAEs), including acute kidney injury.
America’s job market rebounded in November, adding 227,000 workers in a solid recovery from the previous month, when the effects of strikes and hurricanes had sharply diminished employers’ payrolls
U.S. stocks rose to records after data suggested the job market remains solid enough to keep the economy going, but not so strong that it raises immediate worries about inflation
BofA says visit to Giga Texas confirms that FSD progress supports a 2025 robotaxi launch, and Optimus is ‘real’
There are signs that demand for cruises keep growing, with record bookings post-Thanksgiving
ProKidney has stopped one of a pair of phase 3 trials for its cell therapy for kidney disease after deciding it wasn’t essential for securing FDA approval.
Pfizer and Valneva may have about two more years to wait before they make the first approval filing to the FDA for a Lyme disease vaccine, but that hasn’t stopped the companies collecting more positive data in the meantime.
A study from Abbott found that employing its cardiac valve repair implant during earlier phases of heart failure—when a patient’s leaky mitral valve is still considered to be functional—could lead to fewer related hospitalizations while improving health status and quality of life.
The FDA has approved a new type of stent designed specifically for infants and young children—including neonates born with congenital heart defects—that’s designed to expand in size as the child grows.
Arrowhead Pharmaceuticals has shown its hand ahead of a potential showdown with Ionis, publishing phase 3 data on a rare metabolic disease treatment that is racing toward regulators.
Drug based on anti-nausea agent reduces Alzheimer’s-advancing astrocytes in mice, biotech says
FDA elevates recall as Zimmer Biomet phases out hip replacement implant
Alkeus’ oral eye disease asset fails to significantly reduce lesion growth in phase 3
Rakovina deepens AI focus with cancer collab to select DNA-damage response kinase targets
FDA clears Senseonics’ 365-day Eversense CGM implant
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
Ascendis’ dwarfism drug accelerates growth in phase 3, teeing up challenge to BioMarin
Trispecific antibody from Ichnos Glenmark Innovation beats J&J’s Tecvayli at treating multiple myeloma in mice
American Consumers Feeling Less Confident in December, Conference Board Says
Biden Will Decide on US Steel Acquisition After Influential Panel Fails to Reach Consensus
